Champions Oncology Inc (CSBR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Champions Oncology Inc (CSBR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11528
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Champions Oncology Inc (Champions), formerly Champions Biotechnology Inc, is a developer of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is an approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments. It offers personalized tumorgraft development, drug studies and genome sequencing as part of personalized oncology solutions. The company also provides translational oncology solutions to oncologists, pharmaceutical and biotechnology companies. It has operations in the US and the UK. Champions is headquartered in Hackensack, New Jersey, the US.

Champions Oncology Inc (CSBR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Champions Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 11
Champions Oncology Enters into Agreement with AstraZeneca 12
Champions Oncology Enters into Agreement with Addario 13
Addario Lung Cancer Medical Institute, Champions Oncology and ROS1ders Enter into Agreement 14
Champions Oncology Enters into Co-Development Agreement 15
Insilico Medicine Enters into Research Agreement with Champions Oncology 16
Champions Enters Into Drug Discovery And Development Agreement With Teva 17
Licensing Agreements 18
Champions Oncology Enters into Licensing Agreement with Pfizer 18
Equity Offering 19
Champions Oncology Raises USD5 Million in Public Offering of Shares 19
Champions Oncology Raises USD14 Million in Private Placement of Units 21
Champions Oncology Completes Private Placement Of Shares For US$9 Million 23
Champions Oncology Inc – Key Competitors 24
Champions Oncology Inc – Key Employees 25
Champions Oncology Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Mar 16, 2017: Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland 27
Financial Announcements 28
Sep 13, 2018: Champions Oncology reports record quarterly revenue of $6.2 million 28
Jul 26, 2018: Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018 29
Mar 15, 2018: Champions Oncology Reports Quarterly Revenue of $5.1 Million 31
Dec 07, 2017: Champions Oncology Reports Record Quarterly Revenue of $5.2M 33
Sep 14, 2017: Champions Oncology Reports Record Quarterly Revenue of $5 Million 35
Jul 27, 2017: Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017 37
Mar 16, 2017: Champions Oncology Reports 40% Revenue Growth 39
Government and Public Interest 41
Sep 26, 2017: Champions Oncology announces $2 million award from the National Cancer Institute to develop and evaluate prostate cancer PDX models 41
Product News 42
Sep 18, 2017: Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft model responses and patient responses to oncology therapies 42
Feb 16, 2017: Champions Oncology Announces New Collection of Patient-Derived Xenograft Models Available for Translational Research 43
Other Significant Developments 44
Feb 21, 2018: Motivated Patients with ROS1 Cancer Initiate Global Research Study 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Champions Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Champions Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Champions Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 11
Champions Oncology Enters into Agreement with AstraZeneca 12
Champions Oncology Enters into Agreement with Addario 13
Addario Lung Cancer Medical Institute, Champions Oncology and ROS1ders Enter into Agreement 14
Champions Oncology Enters into Co-Development Agreement 15
Insilico Medicine Enters into Research Agreement with Champions Oncology 16
Champions Enters Into Drug Discovery And Development Agreement With Teva 17
Champions Oncology Enters into Licensing Agreement with Pfizer 18
Champions Oncology Raises USD5 Million in Public Offering of Shares 19
Champions Oncology Raises USD14 Million in Private Placement of Units 21
Champions Oncology Completes Private Placement Of Shares For US$9 Million 23
Champions Oncology Inc, Key Competitors 24
Champions Oncology Inc, Key Employees 25
Champions Oncology Inc, Other Locations 26
Champions Oncology Inc, Subsidiaries 26

List of Figures
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Champions Oncology Inc (CSBR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rush Enterprises, Inc.:企業の戦略・SWOT・財務分析
    Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rush Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Newfoundland and Labrador Hydro:企業の戦略的SWOT分析
    Newfoundland and Labrador Hydro - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Naspers Limited (NPN):企業の財務・戦略的SWOT分析
    Naspers Limited (NPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Prolung Inc (LUNG):医療機器:M&Aディール及び事業提携情報
    Summary Prolung Inc(Prolung) formerly known as Fresh Medical Laboratories Inc, is a medical device company that offers diagnostic services. The company offers electro pulmonary nodule scanner system used for the non invasive early diagnostics of different types of diseases. Its EPN system consists o …
  • FMC Corp (FMC):企業の財務・戦略的SWOT分析
    FMC Corp (FMC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Cleco Corporate Holdings, Llc:企業の戦略・SWOT・財務分析
    Cleco Corporate Holdings, Llc - Strategy, SWOT and Corporate Finance Report Summary Cleco Corporate Holdings, Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Hornbeck Offshore Services Inc (HOS):企業の財務・戦略的SWOT分析
    Hornbeck Offshore Services Inc (HOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Aarhus University-製薬・医療分野:企業M&A・提携分析
    Summary Aarhus University (Aarhus) is a university that undertakes activities related to research, talent development, knowledge exchange and education. The university offers bachelor’s degree programmes, master’s degree programmes and PhD programmes in various disciplines. Its areas of academic int …
  • Thermo Fisher Scientific Inc (TMO):企業の財務・戦略的SWOT分析
    Thermo Fisher Scientific Inc (TMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Biotec Pharmacon ASA (BIOTEC):企業の財務・戦略的SWOT分析
    Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a biopharmaceutical company that develops, manufactures and markets immune modulating compounds and cold adapted enzymes. The company provides products which are used in the areas of human medicine such as immunotherapy of cancer, general infection …
  • Kodiak Sciences Inc (KOD):製薬・医療:M&Aディール及び事業提携情報
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjuga …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a developer and manufacturer of prescription and hospital products. The company offers hospital products such as Iomeron and Iopamiro, Multihance, Y Prohance, Sonovue, contrast injection systems, Sodium Heparin and Siklos. Its diagnostic products …
  • Coutts & Co.:企業の戦略・SWOT・財務情報
    Coutts & Co. - Strategy, SWOT and Corporate Finance Report Summary Coutts & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Pierre & Vacances SA (VAC):企業の財務・戦略的SWOT分析
    Pierre & Vacances SA (VAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Bone Biologics Corp (BBLG):製薬・医療:M&Aディール及び事業提携情報
    Summary Bone Biologics Corp (Bone Biologics) is a biotechnology company that develops orthobiologic products. The company develops NELL-1, a recombinant human protein growth factor, which is essential for normal bone development. It offers bone graft substitutes for spine fusion. Bone Biologics also …
  • Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 i …
  • Merus Labs International Inc (MSL):企業の財務・戦略的SWOT分析
    Summary Merus Labs International Inc (Merus Labs International), formerly Merus Labs Inc, a subsidiary of Norgine BV, is a pharmaceutical company that provides medicinal products. The company offers products in the therapeutic areas of cardiovascular, oncology support, women's health, urology, and i …
  • Jcb Co., Ltd.:企業の戦略・SWOT・財務分析
    Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • ELITechGroup Inc:企業の製品パイプライン分析2018
    Summary ELITechGroup Inc (ELITech) is a medical device company that manufactures and distributes in vitro diagnostic equipment and reagents. The company’s products portfolio includes clinical chemistry, cystic fibrosis, hematology, microbiology and molecular diagnostics. Its clinical chemistry produ …
  • Barton Malow Company:戦略・SWOT・企業財務分析
    Barton Malow Company - Strategy, SWOT and Corporate Finance Report Summary Barton Malow Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆